On December 11, 2023, Sangamo Therapeutics, Inc., or Sangamo, and its collaborator, Pfizer, Inc., or Pfizer, presented updated data from the Phase 1/2 Alta study of giroctocogene fitelparvovec, a gene therapy product candidate for the treatment of moderately severe to severe hemophilia A, at the 65 th American Society of Hematology Annual Meeting & Exposition. Giroctocogene fitelparvovec is the subject of the registrational Phase 3 AFFINE clinical trial being conducted by Pfizer. Pfizer expects a pivotal readout in the Phase 3 AFFINE trial evaluating giroctocogene fitelparvovec in the middle of 2024.

A copy of the presentation is filed herewith as Exhibit 99.1 and incorporated by reference herein.